Humacyte, Inc. is an ESG-conscious pharmaceutical company based in the United States, with a Risk Rating Score of 29.9. Specializing in bioengineering human tissues and organs, Humacyte aims to revolutionize healthcare by providing universal implantable solutions for various medical conditions. Their focus on sustainability and governance positions them as a leader in the pharmaceutical industry.